These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16476953)

  • 1. Multiplex analysis of expression of three IFNbeta-induced genes in antibody-positive MS patients.
    Pachner AR; Narayan K; Pak E
    Neurology; 2006 Feb; 66(3):444-6. PubMed ID: 16476953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity.
    Pachner A; Narayan K; Price N; Hurd M; Dail D
    Mol Diagn; 2003; 7(1):17-25. PubMed ID: 14529316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.
    Pachner AR; Dail D; Pak E; Narayan K
    J Neuroimmunol; 2005 Sep; 166(1-2):180-8. PubMed ID: 16005084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.
    Vallittu AM; Halminen M; Peltoniemi J; Ilonen J; Julkunen I; Salmi A; Erälinna JP;
    Neurology; 2002 Jun; 58(12):1786-90. PubMed ID: 12084878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients.
    Malucchi S; Gilli F; Caldano M; Sala A; Capobianco M; di Sapio A; Granieri L; Bertolotto A
    J Neurol; 2011 May; 258(5):895-903. PubMed ID: 21153733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study.
    Pachner AR; Warth JD; Pace A; Goelz S;
    Neurology; 2009 Nov; 73(18):1493-500. PubMed ID: 19884577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB).
    Pachner AR; Bertolotto A; Deisenhammer F
    Neurology; 2003 Nov; 61(9 Suppl 5):S24-6. PubMed ID: 14610107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
    Hesse D; Sellebjerg F; Sorensen PS
    Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
    Bertolotto A; Sala A; Caldano M; Capobianco M; Malucchi S; Marnetto F; Gilli F
    J Immunol Methods; 2007 Apr; 321(1-2):19-31. PubMed ID: 17335844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.
    Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A
    Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.
    Bertolotto A; Gilli F; Sala A; Capobianco M; Malucchi S; Milano E; Melis F; Marnetto F; Lindberg RL; Bottero R; Di Sapio A; Giordana MT
    Neurology; 2003 Feb; 60(4):634-9. PubMed ID: 12601105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.
    Deisenhammer F; Schellekens H; Bertolotto A
    J Neurol; 2004 Jun; 251 Suppl 2():II31-9. PubMed ID: 15264110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosis.
    Malhotra S; Bustamante MF; Pérez-Miralles F; Rio J; Ruiz de Villa MC; Vegas E; Nonell L; Deisenhammer F; Fissolo N; Nurtdinov RN; Montalban X; Comabella M
    PLoS One; 2011; 6(8):e23634. PubMed ID: 21886806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
    Pachner AR; Cadavid D; Wolansky L; Skurnick J
    Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
    Vartanian T; Sölberg Sørensen P; Rice G
    J Neurol; 2004 Jun; 251 Suppl 2():II25-30. PubMed ID: 15264109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.
    Bertolotto A; Malucchi S; Milano E; Castello A; Capobianco M; Mutani R
    Immunopharmacology; 2000 Jul; 48(2):95-100. PubMed ID: 10936507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
    Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
    Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis.
    Gilli F; Marnetto F; Stefanuto G; Rinaldi V; Farinazzo F; Malucchi S; Capobianco M; Caldano M; Sala A; Bertolotto A
    Mol Diagn; 2004; 8(3):185-94. PubMed ID: 15771557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies.
    Scagnolari C; Duda P; Bagnato F; De Vito G; Alberelli A; Lavolpe V; Girardi E; Durastanti V; Trojano M; Kappos L; Antonelli G
    J Neurol; 2007 May; 254(5):597-604. PubMed ID: 17420930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1.
    Feng X; Petraglia AL; Chen M; Byskosh PV; Boos MD; Reder AT
    J Neuroimmunol; 2002 Aug; 129(1-2):205-15. PubMed ID: 12161037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.